Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 9/2022

20-01-2022 | Correspondence

Why stratification is important in primary Sjögren’s syndrome

Authors: D. W. Lendrem, J. R. Tarn, A. Collins, J. Wason, W. F. Ng

Published in: Rheumatology International | Issue 9/2022

Login to get access

Excerpt

We read with great interest the letter by Baicus [1] on the stratification of primary Sjögren’s Syndrome (pSS) [2]. We agree that the discovery of subgroups permitting stratification of pSS could be an important step in the clinical management of patients and the trial design for patients with pSS. In addition to the European cohorts [3], we note that Lee et al. report at least three subgroups in a S Korean cohort with long-term stability of subgroup membership at least over a 5-year period of clinical follow-up [4]. …
Literature
1.
Baicus C (2021) The stratification of primary Sjogren’s syndrome: is it really solving the problem? Rheumatol Int 41(12):2241CrossRef
2.
Collins A, Lendrem D, Wason J, Tarn J, Howard-Tripp N, Bodewes I, Versnel MA, Gottenberg JE, Seror R, Mariette X, Ng WF (2021) Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatol Int 41(9):1593–1600CrossRef
3.
Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V, Seror R, Skelton AJ, James K, McMeekin P, Al-Ali S (2019) Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol 1(2):e85-94CrossRef
4.
Lee JJ, Park YJ, Park M, Yim HW, Park SH, Kwok SK (2021) Longitudinal analysis of symptom-based clustering in patients with primary Sjogren’s syndrome: a prospective cohort study with a 5-year follow-up period. J Transl Med 19(1):1–8CrossRef
5.
Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, Devauchelle-Pensec V (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 312(3):249–258CrossRef
6.
Bowman SJ, Everett CC, O’Dwyer JL, Emery P, Pitzalis C, Ng WF, Pease CT, Price EJ, Sutcliffe N, Gendi NS, Hall FC (2017) Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren’s syndrome. Arthritis Rheumatol 69(7):1440–1450CrossRef
Metadata
Title
Why stratification is important in primary Sjögren’s syndrome
Authors
D. W. Lendrem
J. R. Tarn
A. Collins
J. Wason
W. F. Ng
Publication date
20-01-2022
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 9/2022
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-021-05068-y

Other articles of this Issue 9/2022

Rheumatology International 9/2022 Go to the issue

Observational Research

Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort

Observational Research

Perspectives on applying immuno-autonomics to rheumatoid arthritis: results from an online rheumatologist survey

Case Based Review

Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review

Biomarkers

Assessment of serum and synovial fluid MMP-3 and MPO as biomarkers for psoriatic arthritis and their relation to disease activity indices

Observational Research

Seasonal residual activity in adult familial Mediterranean fever: a longitudinal observational study

Comorbidities

Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits